Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.

@article{Fasanmade2010SerumAC,
  title={Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.},
  author={Adedigbo A. Fasanmade and Omoniyi J. Adedokun and Amanda M Olson and Richard Strauss and Hugh M. Davis},
  journal={International journal of clinical pharmacology and therapeutics},
  year={2010},
  volume={48 5},
  pages={297-308}
}
OBJECTIVES Infliximab, an IgG1 monoclonal antibody (mab), has large inter-individual serum concentration variability. The objective was to determine the extent of the association of baseline albumin concentration and infliximab disposition in patient with ulcerative colitis. METHOD Data from 728 patients with ulcerative colitis from two clinical trials were analyzed to evaluate trends between infliximab pharmacokinetics and serum albumin, or liver or kidney function. Response in the placebo… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 57 extracted citations

Can We Predict the Efficacy of Anti-TNF-α Agents?

International journal of molecular sciences • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…